The increase in the number of drugs targeted for diseases that affect the Central Nervous System has also increased the need for Electroencephalography (EEGs) in clinical research. While EEGs have been commonly used to determine the efficacy of epilepsy drugs, new studies have indicated the effectiveness of this non-invasive imaging modality to determine treatment options for anti-depressants. The recent BRITE (Biomakers for Rapid Identification of Treatment Efficacy in Major Depression) study, which assessed the treatment of major depression in adults, monitored brain activity once a patient began treatment of a new anti-depressant drug. Utilizing an EEG recording of the brain’s activity on drug, the study concluded that it was possible to reduce the time required to determine the effectiveness of that drug from a norm of several weeks to as little as seven days.

Biomedical Systems’ Imaging Services has been a pioneer among the Imaging Core Labs in offering new modalities for clinical trials and is the first to provide Centralized EEG Services. With a team in place that has an expertise in the EEG process and equipment, we work with Sponsors around the globe to develop protocols that reduce timelines and provide quality clinical trial data.